Redemplo is a drug owned by Arrowhead Pharmaceuticals Inc. It is protected by 5 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 10, 2038. Details of Redemplo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10597657 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) |
Sep, 2038
(12 years from now) | Active |
| US12365899 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) |
Sep, 2038
(12 years from now) | Active |
| US11214801 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) |
Sep, 2038
(12 years from now) | Active |
| US10294474 | Targeting Ligands |
Mar, 2037
(10 years from now) | Active |
| US11174481 | Targeting Ligands |
Mar, 2037
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Redemplo's patents.
Latest Legal Activities on Redemplo's Patents
Given below is the list of recent legal activities going on the following patents of Redemplo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 29 Jul, 2025 | US12365899 |
| Email Notification | 23 Jul, 2025 | US12365899 |
| Recordation of Patent eGrant | 22 Jul, 2025 | US12365899 |
| Mail Patent eGrant Notification | 22 Jul, 2025 | US12365899 |
| Patent Issue Date Used in PTA Calculation | 22 Jul, 2025 | US12365899 |
| Patent eGrant Notification | 22 Jul, 2025 | US12365899 |
| Email Notification | 10 Jul, 2025 | US12365899 |
| Issue Notification Mailed | 09 Jul, 2025 | US12365899 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2025 | US11214801 |
| Application Is Considered Ready for Issue | 19 Jun, 2025 | US12365899 |
US patents provide insights into the exclusivity only within the United States, but
Redemplo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Redemplo's family patents as well as insights into
ongoing legal events
on those patents.
Redemplo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Redemplo's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 10, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Redemplo Generics:
There are no approved generic versions for Redemplo as of now.
About Redemplo
Redemplo is a drug owned by Arrowhead Pharmaceuticals Inc. Redemplo uses Plozasiran Sodium as an active ingredient. Redemplo was launched by Arrowhead in 2025.
Approval Date:
Redemplo was approved by FDA for market use on 18 November, 2025.
Active Ingredient:
Redemplo uses Plozasiran Sodium as the active ingredient. Check out other Drugs and Companies using Plozasiran Sodium ingredient
Dosage:
Redemplo is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | SOLUTION | Prescription | SUBCUTANEOUS |